[go: up one dir, main page]

AR082768A1 - Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen - Google Patents

Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen

Info

Publication number
AR082768A1
AR082768A1 ARP110102399A ARP110102399A AR082768A1 AR 082768 A1 AR082768 A1 AR 082768A1 AR P110102399 A ARP110102399 A AR P110102399A AR P110102399 A ARP110102399 A AR P110102399A AR 082768 A1 AR082768 A1 AR 082768A1
Authority
AR
Argentina
Prior art keywords
alk
group
coor5
alkyl
groups
Prior art date
Application number
ARP110102399A
Other languages
English (en)
Inventor
Chantal Alcouffe
Corentin Herbert
Gilbert Lassale
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR082768(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of AR082768A1 publication Critical patent/AR082768A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)

Abstract

Reivindicación 1: Compuesto de fórmula (1) en la que R1 representa un átomo de hidrógeno o de halógeno, un grupo alquilo sustituido opcionalmente con -COOR5, alquenilo sustituido opcionalmente con -COOR5, un grupo -COOR5, -CONR5R6, -NR5COR6, -NR5-SO2R6, -OR5, -O-Alk-OR5, -O-Alk-COOR5, -O-Alk-OR5, -O-Alk-NR5R6, -O-Alk-NR7R8, o un grupo arilo, en particular fenilo, o heteroarilo, estando dicho grupo arilo o heteroarilo sustituido opcionalmente con uno o varios grupos elegidos entre los átomos de halógeno, los grupos alquilo, los grupos cicloalquilo, -COOR5, -CF3, -OCF3, -CN, -C(NH2)NOH, -OR5, -O-Alk-COOR5, -O-Alk-NR5R6, -O-Alk-NR7R8, -Alk-OR5, -Alk-COOR5, -CONR5R6, -CO-NR5-OR6, -CO-NR5-SO2R7, -CONR5-Alk-NR5R6, -CONR5-Alk-NR7R8, -Alk-NR5R6, -NR5R6, -NC(O)N(CH3)2, -CO-Alk, -CO(OAlk)nOH, -COO-AIkNR5R6, COOAlk-NR7R8 y los grupos heteroarilo de 5 eslabones, estando dichos grupos heteroarilo sustituidos opcionalmente con uno o varios grupos elegidos entre los átomos de halógeno y los grupos alquilo, -CF3, -CN, -COOR5, -Alk-OR5, -Alk-COOR5, -CONR5R6, -CONR7R8, -CO-NR5-OR6, -CO-NR5-SO2R7 y -NR5R5, -Alk-NR5R6, o con un grupo hidroxilo o con un átomo de oxígeno; n es un número entero que va de 1 a 3; R2 representa un átomo de hidrógeno, un grupo alquilo, un grupo fenilo sustituido opcionalmente con uno o varios grupos alquilo, R3 y R4 forman conjuntamente, con los átomos de carbono del núcleo fenilo al que están unidos, un heterociclo nitrogenado de 6 eslabones que responde a una de las fórmulas (A), (B) ó (C) en las que los trazos ondulados representan el núcleo fenilo al que están unidos R3 y R4; y Ra representa un átomo de hidrógeno o un grupo alquilo, halógenoalquilo, -Alk-CF3, -Alk-COOR5, -Alk’-COOR5, -Alk-CONR5R6, -Alk’-CONR5R6, -Alk-CONR7R8, -Alk-NR5R6, -AIkCONR5-OR6, -Alk-NR7R8, -Alk-cicloalquilo, -Alk-OR5, -Alk-S-R5, -Alk-CN, -OR5, -OAIkCOOR5, -NR5R6, -NR5-COOR6, -Alk-arilo, -Alk-O-arilo, -Alk-O-heteroarilo, -Alk-heteroarilo o heteroarilo en el que el grupo arilo o heteroarilo está sustituido opcionalmente con uno o varios átomos de halógeno y/o grupos alquilo, cicloalquilo, -CF3, -OCF3, -O-R5 o -S-R5; Ra’ representa un átomo de hidrógeno o un grupo alquilo, lineal, ramificado, cíclico o parcialmente cíclico, o un grupo -Alk-OR5 o -Alk-NR5R6, -Alk-NR7R8, estando Ra’ sustituido opcionalmente con uno o varios átomos de halógeno; Rb representa un átomo de hidrógeno o un grupo alquilo o -Alk-COOR5; Rb’ representa un átomo de hidrógeno o un grupo alquilo, halógenoalquilo, cicloalquilo, fenilo o -Alk-COOR5; Rc representa un átomo de hidrógeno o un grupo alquilo, -CN, -COOR5, -CO-NR5R5, -CONR7R8, -CO-NR5-Alk-NR5R6, -CONR5-Alk-OR5, CONR5SO2R5, o -Alk-arilo, -Alk-heteroarilo, en el que el grupo arilo o heteroarilo está sustituido opcionalmente con uno o varios átomos de halógeno y/o grupos alquilo, cicloalquilo, -CF3, -OCF3, -O-alquilo o -S-alquilo; Rc’ representa un átomo de hidrógeno o un grupo alquilo; Rc’’ representa un átomo de hidrógeno o un grupo alquilo, alquenilo, halógenoalquilo, cicloalquilo, -Alk-NR5R6, -Alk-NR7R8, -Alk-OR5, -Alk-SR5; R5 y R6, idénticos o diferentes, representan átomos de hidrógeno, grupos halógenoalquilo o grupos alquilo, grupos cicloalquilo, un grupo Ms; R7 y R8, idénticos o diferentes, representan átomos de hidrógeno o grupos alquilo o fenilo, o bien R7 y R8 forman conjuntamente un ciclo saturado de 3 a 8 eslabones que puede contener opcionalmente un heteroátomo; Alk representa una cadena alquileno lineal o ramificada; y Alk’ representa una cadena alquileno lineal, ramificada, cíclica o parcialmente cíclica; opcionalmente en la forma de una de sus sales farmacéuticamente aceptables.
ARP110102399A 2010-07-06 2011-07-05 Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen AR082768A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1055477A FR2962438B1 (fr) 2010-07-06 2010-07-06 Derives d'indolizines, procedes de preparation et application en therapeutique

Publications (1)

Publication Number Publication Date
AR082768A1 true AR082768A1 (es) 2013-01-09

Family

ID=43382527

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110102399A AR082768A1 (es) 2010-07-06 2011-07-05 Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen

Country Status (39)

Country Link
US (1) US8859544B2 (es)
EP (1) EP2590975B1 (es)
JP (1) JP5863788B2 (es)
KR (1) KR101797795B1 (es)
CN (1) CN103080112B (es)
AR (1) AR082768A1 (es)
AU (1) AU2011275426B2 (es)
BR (1) BR112013000306A2 (es)
CA (1) CA2805065C (es)
CL (1) CL2013000018A1 (es)
CO (1) CO6650361A2 (es)
CR (1) CR20130001A (es)
CY (1) CY1116945T1 (es)
DK (1) DK2590975T3 (es)
DO (1) DOP2012000321A (es)
EA (1) EA024160B1 (es)
EC (1) ECSP13012362A (es)
ES (1) ES2552850T3 (es)
FR (1) FR2962438B1 (es)
GT (1) GT201300001A (es)
HR (1) HRP20151162T1 (es)
HU (1) HUE026067T2 (es)
IL (1) IL223844A (es)
MA (1) MA34451B1 (es)
MX (1) MX2012015306A (es)
MY (1) MY163202A (es)
NI (1) NI201200191A (es)
PE (1) PE20130386A1 (es)
PH (1) PH12013500005A1 (es)
PL (1) PL2590975T3 (es)
PT (1) PT2590975E (es)
SG (2) SG186436A1 (es)
SI (1) SI2590975T1 (es)
TN (1) TN2012000609A1 (es)
TW (1) TWI494310B (es)
UA (1) UA109013C2 (es)
UY (1) UY33489A (es)
WO (1) WO2012004731A1 (es)
ZA (1) ZA201300100B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
CN107652289B (zh) 2012-06-13 2020-07-21 因塞特控股公司 作为fgfr抑制剂的取代的三环化合物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
KR102269032B1 (ko) 2013-04-19 2021-06-24 인사이트 홀딩스 코포레이션 Fgfr 저해제로서 이환식 헤테로사이클
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3242878B1 (en) * 2015-01-08 2020-10-14 Impetis Biosciences Ltd. Bicyclic compounds, compositions and medicinal applications thereof
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
AU2016325601C1 (en) * 2015-09-25 2022-03-31 Ludwig Institute For Cancer Research Ltd. 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
CN106045994A (zh) * 2016-06-12 2016-10-26 上海大学 全氟烷基吲嗪衍生物及其合成方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
SG11202010636VA (en) 2018-05-04 2020-11-27 Incyte Corp Solid forms of an fgfr inhibitor and processes for preparing the same
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076602A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JP7720840B2 (ja) 2019-12-04 2025-08-08 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式複素環
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116462A1 (en) 2002-12-12 2004-06-17 Mitsunori Ono Indolizine compounds
ATE370145T1 (de) 2002-04-03 2007-09-15 Bristol Myers Squibb Co Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
FR2859997B1 (fr) 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.
ES2361835T3 (es) 2003-09-25 2011-06-22 Janssen Pharmaceutica Nv Derivados de purina inhibidores de la replicación del hiv.
FR2865934B1 (fr) * 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
FR2893616B1 (fr) 2005-11-23 2008-01-04 Sanofi Aventis Sa Nouveaux derives d'indolizine, leur procede de preparation et les compositions therapeutiques les comprenant
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP1891955A1 (en) * 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases

Also Published As

Publication number Publication date
IL223844A (en) 2016-03-31
US20130116249A1 (en) 2013-05-09
EA024160B1 (ru) 2016-08-31
PE20130386A1 (es) 2013-04-11
SG10201505282YA (en) 2015-08-28
KR20130128362A (ko) 2013-11-26
AU2011275426B2 (en) 2016-05-12
HRP20151162T1 (hr) 2015-12-04
MY163202A (en) 2017-08-15
ES2552850T3 (es) 2015-12-02
CN103080112A (zh) 2013-05-01
WO2012004731A1 (en) 2012-01-12
CY1116945T1 (el) 2017-04-05
JP2013530210A (ja) 2013-07-25
PT2590975E (pt) 2015-11-24
CL2013000018A1 (es) 2013-05-10
ZA201300100B (en) 2014-03-26
JP5863788B2 (ja) 2016-02-17
MA34451B1 (fr) 2013-08-01
UA109013C2 (en) 2015-07-10
PH12013500005A1 (en) 2013-02-18
DK2590975T3 (en) 2015-12-07
SG186436A1 (en) 2013-01-30
FR2962438B1 (fr) 2012-08-17
TW201206931A (en) 2012-02-16
PL2590975T3 (pl) 2016-01-29
EP2590975A1 (en) 2013-05-15
CA2805065C (en) 2018-07-03
SI2590975T1 (sl) 2015-12-31
KR101797795B1 (ko) 2017-11-15
HUE026067T2 (en) 2016-05-30
CO6650361A2 (es) 2013-04-15
BR112013000306A2 (pt) 2020-08-04
DOP2012000321A (es) 2013-04-15
UY33489A (es) 2012-01-31
EA201291409A1 (ru) 2013-05-30
MX2012015306A (es) 2013-04-29
ECSP13012362A (es) 2013-01-31
US8859544B2 (en) 2014-10-14
CR20130001A (es) 2013-02-05
CA2805065A1 (en) 2012-01-12
TWI494310B (zh) 2015-08-01
FR2962438A1 (fr) 2012-01-13
NI201200191A (es) 2013-05-13
TN2012000609A1 (en) 2014-04-01
GT201300001A (es) 2014-04-29
CN103080112B (zh) 2016-04-20
AU2011275426A1 (en) 2013-01-24
EP2590975B1 (en) 2015-08-19

Similar Documents

Publication Publication Date Title
AR082768A1 (es) Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
AR082112A1 (es) Derivados de imidazopiridina, su procedimiento de preparacion y su aplicacion en terapeutica
PE20160661A1 (es) Compuesto de azapiridona y sus usos de los mismos
CO6210729A2 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico
CR20140133A (es) Compuestos de piridazinona y sus usos como inhibidores de daao
AR091498A1 (es) DERIVADOS DE 2,3-DIHIDRO-1H-IMIDAZO{1,2-a}PIRIMIDIN-5-ONA Y 1,2,3,4-TETRAHIDRO-PIRIMIDO{1,2-a}PIRIMIDIN-6-ONA QUE CONTIENEN UNA MORFOLINA SUSTITUIDA, SU PREPARACION Y SU UTILIZACION FARMACEUTICA
AR083199A1 (es) Compuestos de n-heteroarilo con unidad de puente ciclico
CR20140089A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
CR20120418A (es) Inhibidores de virus flaviviridae
UY39338A (es) Derivados de piperidinona como inhibidores mdm2, composiciones farmacéuticas que los contienen y sus usos
CR20140091A (es) Nuevos derivados dihidroquinolina-2-ona
UY34888A (es) Inhibidores del virus de la hepatitis c
AR083200A1 (es) Compuestos de n-heteroarilo
AR082414A1 (es) Carboxamidas azaheterociclicas biciclicas utiles para tratar enfermedades hiperproliferativas e inflamatorias, composiciones farmaceuticas que las contienen y procedimiento para prepararlas
AR075737A1 (es) SALES DE ADICIoN DE TROMETAMINA CON DERIVADOS DE ACIDO AZABIFENILAMINOBENZOICO COMO INHIBIDORES DE DHODH Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENE
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
SV2009003199A (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR095164A1 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
UY32635A (es) Derivados de bis-(sulfonilamino) en terapia 735
AR072880A1 (es) Derivados nitrogenados de la pancratistatina
AR083987A1 (es) Amidas de acido pirazolcarboxilico utiles para la reduccion de la contaminacion de micotoxina en las plantas
AR093168A1 (es) COMPUESTOS DE OXAZOLIDINONA COMO INHIBIDORES DEL CANAL KCa3.1
UY32756A (es) Nuevos derivados de 1h-pirimidin-2-ona, su preparacion y su utilizacion farmaceutica como inhibidores de la fos-forilacion de akt (pkb)
CU20100149A7 (es) Nuevos derivados croménicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY33927A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FC Refusal